NCT00562549

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

A Pilot Phase IIa Randomised, Double-blind, Placebo-controlled, Crossover Study to Examine the Safety, Tolerability and Pharmacodynamic Effects on Blood Pressure of Repeat Oral Doses of SLx-2101 5, 10 or 20 mg Once Daily for up to 14 Days in Patients With Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Response Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.

Detailed description

1. Office seated peripheral systolic and diastolic blood pressure 2. Adverse events and vital signs 3. Plasma concentrations of SLx-2101

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	SLx-2101

Timeline

• Start date: 2007-07-01
• Primary completion: 2007-12-01
• Completion: 2007-12-01
• First posted: 2007-11-22
• Last updated: 2023-05-03

Locations

1 site across 1 country: United Kingdom